Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients.
adenosarcomas
endometrial stromal sarcomas
leiomyosarcomas
morcellation
prognosis
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
03
2019
accepted:
21
06
2019
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
24
8
2019
Statut:
epublish
Résumé
We conducted this study to explore the clinical characteristics, prognosis, and prevalence of unexpected uterine sarcoma (UUS) after hysterectomy and myomectomy for presumed leiomyoma. The records of women who underwent hysterectomy or myomectomy through laparoscopy or laparotomy for preoperatively presumed uterine leiomyomas from January 2009 to December 2016 were reviewed and data were retrospectively analyzed. Eleven patients had morcellation of uterine sarcoma. Eighty-eight patients were diagnosed with uterine sarcomas (total prevalence: 0.33%) including 29 leiomyosarcomas (LMS), 48 endometrial stromal sarcomas (ESS), and 11 adenosarcomas. ESS patients with advanced stage were significantly associated with worse overall survival ( Only 0.33% of patients who underwent surgery for presumed leiomyoma experienced UUS, and advanced stage seemed to be the single prognostic factor for sarcoma. However, the time interval between initial treatment and secondary definitive surgery was not shown to impact prognosis. In addition, the small number of UUS patients having morcellation (4 LMS and 7 ESS) may be underpowered to detect differences in survival.
Identifiants
pubmed: 31440089
doi: 10.2147/CMAR.S208405
pii: 208405
pmc: PMC6664248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7007-7014Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1320-9
pubmed: 11955745
Obstet Gynecol. 1992 Apr;79(4):481-4
pubmed: 1553162
Science. 2005 Jun 10;308(5728):1589-92
pubmed: 15947177
Int J Gynaecol Obstet. 2009 Mar;104(3):177-8
pubmed: 19135669
Histopathology. 2009 Feb;54(3):355-64
pubmed: 19236512
Gynecol Oncol. 2010 Jan;116(1):131-9
pubmed: 19853898
Semin Reprod Med. 2010 May;28(3):204-17
pubmed: 20414843
Gynecol Oncol. 2011 May 1;121(2):328-33
pubmed: 21316747
Gynecol Oncol. 2011 Aug;122(2):255-9
pubmed: 21565389
Am J Obstet Gynecol. 2012 Mar;206(3):211.e1-9
pubmed: 22244472
Ann Oncol. 2012 Sep;23 Suppl 10:x151-7
pubmed: 22987952
Gynecol Oncol. 2014 Feb;132(2):360-5
pubmed: 24296345
Int J Clin Exp Pathol. 2014 Mar 15;7(4):1616-24
pubmed: 24817958
Int J Gynecol Cancer. 2014 Jul;24(6):1027-32
pubmed: 24927246
J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):410-4
pubmed: 25460521
Am J Obstet Gynecol. 2015 May;212(5):594.e1-10
pubmed: 25499259
Obstet Gynecol. 2015 Feb;125(2):397-405
pubmed: 25569001
Gynecol Oncol. 2015 Jun;137(3):581-8
pubmed: 25805398
J Minim Invasive Gynecol. 2015 Sep-Oct;22(6):1068-74
pubmed: 26070730
Onco Targets Ther. 2015 Oct 15;8:2943-8
pubmed: 26508879
Obstet Gynecol. 2016 Jan;127(1):29-39
pubmed: 26646120
J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):384-9
pubmed: 26677821
Best Pract Res Clin Obstet Gynaecol. 2016 Jul;34:3-12
pubmed: 26725703
Int J Gynecol Cancer. 2016 Mar;26(3):456-63
pubmed: 26807642
Obstet Gynecol. 2016 Mar;127(3):468-73
pubmed: 26855091
BMC Cancer. 2016 Aug 23;16(1):675
pubmed: 27553655
Curr Oncol Rep. 2016 Nov;18(11):68
pubmed: 27718181
JAMA Surg. 2017 Feb 1;152(2):143-149
pubmed: 27784058
J Obstet Gynaecol Res. 2017 Mar;43(3):580-586
pubmed: 28120430
J Minim Invasive Gynecol. 2017 May - Jun;24(4):659-664
pubmed: 28216458
Gynecol Oncol. 2017 Apr;145(1):61-70
pubmed: 28317559
Int J Gynecol Cancer. 2017 Jun;27(5):973-978
pubmed: 28498251
Chin Med J (Engl). 2017 Nov 20;130(22):2661-2665
pubmed: 29133752